Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems

By David Jagielski, CPA – Apr 27, 2026 at 11:00AM ESTKey PointsInvestors have grown excited about Revolution Medicines due to its promising pancreatic cancer drug, daraxonrasib.Daraxonrasib significantly extended the life of patients in a recent clinical trial.The company generates no sales today, but that could change in the future.If a stock has a market cap of nearly $30 billion, you would probably expect its business to be well developed, generating significant revenue, and likely profitable. But there's one stock trading at a valuation that not only isn't profitable but also isn't generating any revenue right now: Revolution Medicines (RVMD 2.73%). In the past 12 months, its shares have skyrocketed more than 250%. It's been a hot stock to own, even though, from a fundamental approach, it doesn't appear to have much to back up its hefty valuation. And while its valuation is incredibly high, it may not necessarily be all that ridiculous when you consider the long-term growth potential it possesses. Image source: Getty Images. Revolution has some highly promising assets in its portfolio Although the company doesn't have an approved product in its portfolio just yet, it's getting close to that stage. Daraxonrasib is an exciting drug that has shown incredible potential in treating pancreatic cancer. In a recent clinical study, it appeared to significantly extend patients' lives. Those who took chemotherapy lived an average of 6.7 months, whereas the median survival for patients taking daraxonrasib was 13.2 months. Analysts project that daraxonrasib's peak sales could top more than $7 billion. The company also has other cancer drugs, zoldonrasib and elironrasib, which may generate billions in additional revenue. Thus, its valuation may start to look much more reasonable given all that potential growth. ExpandNASDAQ: RVMDRevolution MedicinesToday's Change(-2.73%) $-3.70Current Price$131.60Key Data PointsMarket Cap$28BDay's Range$131.10 - $137.2452wk Range$34.00 - $155.70Volume44KAvg Vol2.9M Has Revolution Medicines' stock become too expensive to buy right now? There's a lot of excitement around Revolution Medicines' stock today, but the danger is that investors may be pricing in too much future growth already. If you look at its possible revenue being upwards of $10 billion or more, you may conclude that at just three times its future revenue (or perhaps even less), it's not all that expensive. But it could take many years for the business to get to the stage where its revenue becomes that large. And that isn't factoring in what its profit will be like, how much cash it might be burning through, and how many shares it will need to issue to facilitate its growth. Plus, there's also the uncertainty around whether all of its promising drugs will obtain approval and whether those rosy analyst estimates will prove to be correct. There's simply a ton of uncertainty around the business, far too much for the stock to be worth its current valuation. The problem with buying the stock at its current level is that there's virtually no margin of safety, and the danger is that if anything goes wrong, the pharma stock may be due for a steep decline.

While Revolution Medicines' valuation may be somewhat justifiable, it's certainly not low, and buying the stock at its current price comes with significant risks.Read NextApr 27, 2026 •By James BrumleyWhy Sagimet Biosciences Stock Is Soaring TodayApr 27, 2026 •By Keith SpeightsIs Bristol Myers Squibb the Best Bargain in Big Pharma?Apr 26, 2026 •By Jack DelaneyBristol Myers Squibb: Low Volatility Meets High Dividend YieldApr 26, 2026 •By David Jagielski, CPAIs It Safe to Buy UnitedHealth Stock Again?Apr 26, 2026 •By James BrumleyThis Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall StreetApr 25, 2026 •By Selena MaranjianShould You Add a Healthcare Stock to Your Portfolio This Month?

And Should It Be Eli Lilly (LLY)?About the AuthorDavid Jagielski, CPA, has been a contributing Motley Fool stock market analyst covering healthcare, consumer staples, consumer discretionary, and technology stocks since 2017. David has more than 10 years of experience in finance roles across businesses of different sizes and sectors. He holds a Certified Public Accountant designation in Canada.TMFdjagielskiStocks MentionedRevolution MedicinesNASDAQ: RVMD$131.60(-2.73%)-$3.70*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.